Cargando…

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma

Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance. We determined whether a demethylating drug, decitabine, could augment the anti-proliferative and apoptotic effects of cis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viet, Chi T., Dang, Dongmin, Achdjian, Stacy, Ye, Yi, Katz, Samuel G., Schmidt, Brian L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229295/ https://www.ncbi.nlm.nih.gov/pubmed/25391133 http://dx.doi.org/10.1371/journal.pone.0112880

Ejemplares similares

Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
por: KjellÃ©n, E., et al.
Publicado: (1989)

Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
por: Griso, Ana Belén, et al.
Publicado: (2022)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma
por: Sheng, Shuyan, et al.
Publicado: (2022)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
por: Abdulla, Mohamed, et al.
Publicado: (2023)

Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma
por: Garcia-Mayea, Yoelsis, et al.
Publicado: (2022)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy
por: Wang, Wenlun, et al.
Publicado: (2023)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
por: Liu, Shutong, et al.
Publicado: (2017)

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
por: Yang, Zejia, et al.
Publicado: (2019)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma
por: Jiang, Minghong, et al.
Publicado: (2011)

NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment
por: Wang, Yi-Fen, et al.
Publicado: (2014)

S-nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma()
por: Kaliyaperumal, Kolanjiappan, et al.
Publicado: (2015)

Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma
por: Bryant, Jennifer, et al.
Publicado: (2019)

Acquisition of Cisplatin Resistance Shifts Head and Neck Squamous Cell Carcinoma Metabolism toward Neutralization of Oxidative Stress
por: Yu, Wangjie, et al.
Publicado: (2020)

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
por: Porceddu, Sandro V., et al.
Publicado: (2020)

Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases
por: Bostan, Marinela, et al.
Publicado: (2019)

Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients
por: Ferreira, Ana Maria Castro, et al.
Publicado: (2023)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Profiles of immune cell infiltration in head and neck squamous carcinoma
por: Liang, Bin, et al.
Publicado: (2020)

Cutaneous Squamous Cell Carcinoma of the Head and Neck
por: Gurudutt, Vivek V., et al.
Publicado: (2011)

Hypoxia in Head and Neck Squamous Cell Carcinoma
por: Li, John Zenghong, et al.
Publicado: (2012)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Exosomes in Head and Neck Squamous Cell Carcinoma
por: Xiao, Cheng, et al.
Publicado: (2019)

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
por: Kim, J G, et al.
Publicado: (2005)

Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors
por: Hitt, R, et al.
Publicado: (2004)

NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC)()
por: Almeida, Luciana O., et al.
Publicado: (2013)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
por: Huang, Kie Kyon, et al.
Publicado: (2016)

Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
por: GAO, JIAN, et al.
Publicado: (2016)

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_se1ql7egtau58gdbscf8pas53q